Publications

Titlesort ascending Year
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening 2018
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening 2019
The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme 2022
The FICI paradigm: correcting flaws in antimicrobial in vitro synergy screens at their inception. 2019
Targeting Tuberculosis: Existing drugs can – and should – be repurposed to fight neglected diseases. 2017
Targeting Tuberculosis: Existing drugs can - and should - be repurposed to fight neglected diseases. 2017
Sanfetrinem, repurposing an oral beta-lactam with intracellular activity for the treatment of tuberculosis 2019
Repurposing β-Lactams for the Treatment of Mycobacterium kansasii Infections: An In Vitro Study 2023
Repurposing clinically approved cephalosporins for tuberculosis therapy. 2016
Repurposing Avermectins and Milbemycins against Mycobacteroides abscessus and Other Nontuberculous Mycobacteria 2021
Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency 2020
Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium 2023
Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial) 2022
Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains. 2013